Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
NCT ID: NCT00795093
Last Updated: 2010-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
552 participants
OBSERVATIONAL
2008-11-30
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France
NCT00842855
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
NCT00703534
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
NCT00394472
What is the Predictive Value of the Reflux Impact Scale
NCT00536328
Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response
NCT00392002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
552 GERD patients, partial responders to PPI treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treated with unchanged optimized PPI treatment for any GERD indication during a consecutive 4 week period
* Remaining GERD symptoms despite optimized PPI treatment
* Able to read and write in US English, and able to comply with study requirements
Exclusion Criteria
* Involvement in the planning or conduct of the study
* Involvement in any other observational study or in any clinical study at the time of this study or during the last 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
i3 Innovus
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca R&D
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meg Good
Role: PRINCIPAL_INVESTIGATOR
i3 Innovus
Marie Sundin
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Leeds, Alabama, United States
Research Site
Pheonix, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Concord, California, United States
Research Site
Lancaster, California, United States
Research Site
Los Banos, California, United States
Research Site
Solana Beach, California, United States
Research Site
Newark, Delaware, United States
Research Site
Altamonte Springs, Florida, United States
Research Site
Cocoa, Florida, United States
Research Site
DeFuniak Springs, Florida, United States
Research Site
Largo, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Naples, Florida, United States
Research Site
Ocala, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Palm Harbor, Florida, United States
Research Site
Peonia, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Columbus, Georgia, United States
Research Site
Roswell, Georgia, United States
Research Site
Royston, Georgia, United States
Research Site
Snellville, Georgia, United States
Research Site
Belleville, Illinois, United States
Research Site
Mishawaka, Indiana, United States
Research Site
Metaire, Louisiana, United States
Research Site
Prince Frederick, Maryland, United States
Research Site
Towson, Maryland, United States
Research Site
Florissant, Missouri, United States
Research Site
Jefferson City, Missouri, United States
Research Site
Atco, New Jersey, United States
Research Site
Fair Lawn, New Jersey, United States
Research Site
Cary, North Carolina, United States
Research Site
Elkin, North Carolina, United States
Research Site
New Bern, North Carolina, United States
Research Site
Stanley, North Carolina, United States
Research Site
Statesville, North Carolina, United States
Research Site
Beachwood, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Vandalia, Ohio, United States
Research Site
Aliquippa, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Warwick, Rhode Island, United States
Research Site
Charleston, South Carolina, United States
Research Site
Athens, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Irving, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Marcos, Texas, United States
Research Site
Southlake, Texas, United States
Research Site
West Jordan, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9120N00005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.